ArticleNature communications2026
Macrophage INSIG1 deficiency drives psoriasiform dermatitis via the SREBP2-STAT1 axis.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Psoriasis is an autoimmune skin disease, and its pathogenesis remains incompletely understood. As central drivers of psoriasis pathogenesis that bridge innate and adaptive immunity, macrophages are known to be modulated in their function by insulin-induced gene 1 (INSIG1), a regulator of cholesterol synthesis. Bioinformatic analysis of human psoriatic lesions reveals a significant negative correlation between INSIG1 expression and pro-inflammatory cytokine levels (IL-23, IL-17A). Single-cell RNA sequencing (scRNA-seq) and immunofluorescence confirm significantly reduced INSIG1 expression specifically in macrophages from psoriatic skin. In vivo, myeloid-specific Insig1 deficiency exacerbates imiquimod (IMQ)-induced psoriasiform dermatitis, characterized by increased epidermal thickening and immune infiltration. By activating sterol regulatory element-binding protein 2 (SREBP2), INSIG1 deficiency leads to the transcriptional upregulation of STAT1, which drives M1 macrophage polarization and ultimately amplifies psoriatic inflammation. This study reveals an important role of macrophage INSIG1 in regulating inflammatory responses and lipid metabolism, providing insight into the pathogenesis of psoriasis and potential therapeutic targets.
Indexed as
Identifiers
42393041What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.